Cargando…

Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway

Epalrestat is a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy. This study assumed that epalrestat had a protective effect on diabetic peripheral nerve injury by suppressing the expression of aldose reductase in peripheral nerves of diabetes me...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qing-rong, Wang, Zhuo, Zhou, Wei, Fan, Shou-rui, Ma, Run, Xue, Li, Yang, Lu, Li, Ya-shan, Tan, Hong-li, Shao, Qing-hua, Yang, Hong-ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811002/
https://www.ncbi.nlm.nih.gov/pubmed/27073391
http://dx.doi.org/10.4103/1673-5374.177745
_version_ 1782423883717017600
author Li, Qing-rong
Wang, Zhuo
Zhou, Wei
Fan, Shou-rui
Ma, Run
Xue, Li
Yang, Lu
Li, Ya-shan
Tan, Hong-li
Shao, Qing-hua
Yang, Hong-ying
author_facet Li, Qing-rong
Wang, Zhuo
Zhou, Wei
Fan, Shou-rui
Ma, Run
Xue, Li
Yang, Lu
Li, Ya-shan
Tan, Hong-li
Shao, Qing-hua
Yang, Hong-ying
author_sort Li, Qing-rong
collection PubMed
description Epalrestat is a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy. This study assumed that epalrestat had a protective effect on diabetic peripheral nerve injury by suppressing the expression of aldose reductase in peripheral nerves of diabetes mellitus rats. The high-fat and high-carbohydrate model rats were established by intraperitoneal injection of streptozotocin. Peripheral neuropathy occurred in these rats after sustaining high blood glucose for 8 weeks. At 12 weeks after streptozotocin injection, rats were intragastrically administered epalrestat 100 mg/kg daily for 6 weeks. Transmission electron microscope revealed that the injuries to myelinated nerve fibers, non-myelinated nerve fibers and Schwann cells of rat sciatic nerves had reduced compared to rats without epalrestat administuation. Western blot assay and immunohistochemical results demonstrated that after intervention with epalrestat, the activities of antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidase gradually increased, but aldose reductase protein expression gradually diminished. Results confirmed that epalrestat could protect against diabetic peripheral neuropathy by relieving oxidative stress and suppressing the polyol pathway.
format Online
Article
Text
id pubmed-4811002
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-48110022016-04-12 Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway Li, Qing-rong Wang, Zhuo Zhou, Wei Fan, Shou-rui Ma, Run Xue, Li Yang, Lu Li, Ya-shan Tan, Hong-li Shao, Qing-hua Yang, Hong-ying Neural Regen Res Research Article Epalrestat is a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy. This study assumed that epalrestat had a protective effect on diabetic peripheral nerve injury by suppressing the expression of aldose reductase in peripheral nerves of diabetes mellitus rats. The high-fat and high-carbohydrate model rats were established by intraperitoneal injection of streptozotocin. Peripheral neuropathy occurred in these rats after sustaining high blood glucose for 8 weeks. At 12 weeks after streptozotocin injection, rats were intragastrically administered epalrestat 100 mg/kg daily for 6 weeks. Transmission electron microscope revealed that the injuries to myelinated nerve fibers, non-myelinated nerve fibers and Schwann cells of rat sciatic nerves had reduced compared to rats without epalrestat administuation. Western blot assay and immunohistochemical results demonstrated that after intervention with epalrestat, the activities of antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidase gradually increased, but aldose reductase protein expression gradually diminished. Results confirmed that epalrestat could protect against diabetic peripheral neuropathy by relieving oxidative stress and suppressing the polyol pathway. Medknow Publications & Media Pvt Ltd 2016-02 /pmc/articles/PMC4811002/ /pubmed/27073391 http://dx.doi.org/10.4103/1673-5374.177745 Text en Copyright: © Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Research Article
Li, Qing-rong
Wang, Zhuo
Zhou, Wei
Fan, Shou-rui
Ma, Run
Xue, Li
Yang, Lu
Li, Ya-shan
Tan, Hong-li
Shao, Qing-hua
Yang, Hong-ying
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
title Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
title_full Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
title_fullStr Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
title_full_unstemmed Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
title_short Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
title_sort epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811002/
https://www.ncbi.nlm.nih.gov/pubmed/27073391
http://dx.doi.org/10.4103/1673-5374.177745
work_keys_str_mv AT liqingrong epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT wangzhuo epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT zhouwei epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT fanshourui epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT marun epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT xueli epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT yanglu epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT liyashan epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT tanhongli epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT shaoqinghua epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway
AT yanghongying epalrestatprotectsagainstdiabeticperipheralneuropathybyalleviatingoxidativestressandinhibitingpolyolpathway